OnCall

In this episode, the final of our 505(b)(2) series, sponsored by Avyxa, we are joined by Dr. Fred Divers, Chief Medical Officer for American Oncology Network, and Dr. Ralph Boccia, hematologist oncologist, member of American Oncology Network, and the International Oncology Network's Chief Medical Officer, who will discuss operationalizing in practice from a provider perspective.If you have questions for our guests, or suggestions for future topics, email us at OnCallGPO@cencora.comDisclaimer: The OnCall podcast is for educational purposes only and not a substitute for any professional medical advice, legal advice, or clinical judgment. Views expressed are opinions only and not endorsed by Cencora or any of its affiliates. The opinions expressed are solely those of the author and may include certain marketing statements. The content of this presentation is owned or licensed by Cencora, and reproduction of the content is not permitted without Cencora's consent. Neither OnCall nor Cencora control the accuracy of any third-party information. Accessing any referenced site is subject to such site's terms of use.

In this episode, the fourth of our 505(b)(2) series, sponsored by Avyxa, we are joined by James Gilmore, Chief Pharmacy and Clinical Services Officer at American Oncology Network, and Joe Shupp, VP of Sales for Cencora's ION Oncology Network, who will discuss operationalizing in practice from a pharmacist perspective.If you have questions for our guests or suggestions for future topics, send us an email at OnCallGPO@cencora.com.Disclaimer: The OnCall podcast is for educational purposes only and not a substitute for any professional medical advice, legal advice, or clinical judgment. Views expressed are opinions only and not endorsed by Cencora or any of its affiliates. The opinions expressed are solely those of the author and may include certain marketing statements. The content of this presentation is owned or licensed by Cencora, and reproduction of the content is not permitted without Cencora's consent. Neither OnCall nor Cencora control the accuracy of any third-party information. Accessing any referenced site is subject to such site's terms of use.

In this episode, the third of our 505(b)(2) series, sponsored by Avyxa, we are joined by Jonas Congelli, Chief Strategy Officer at Hematology-Oncology Associates of Central New York, Kyle Kitchen, Senior Director at Utah Cancer Specialists, and Trey McNiel, Senior Director of Sales for Cencora's ION Oncology Network East Region, discuss billing and reimbursement of 505(b)(2)s.If you have questions for our guests or suggestions for future topics, send us an email at OnCallGPO@cencora.com.Disclaimer: The OnCall podcast is for educational purposes only and not a substitute for any professional medical advice, legal advice, or clinical judgment. Views expressed are opinions only and not endorsed by Cencora or any of its affiliates. The opinions expressed are solely those of the author and may include certain marketing statements. The content of this presentation is owned or licensed by Cencora, and reproduction of the content is not permitted without Cencora's consent. Neither OnCall nor Cencora control the accuracy of any third-party information. Accessing any referenced site is subject to such site's terms of use.

In this episode, the second of our 505(b)(2) series, sponsored by Avyxa, we are joined by Jonas Congelli, Chief Strategy Officer at Hematology-Oncology Associates of Central New York, Kyle Kitchen, Senior Director at Utah Cancer Specialists, and Matthew Letow, Senior Director of Sales New Business Development for Cencora's SAN GPO National Accounts, who will discuss the landscape and pipeline of 505(b)(2)s.If you have questions for our guests or suggestions for future topics, send us an email at OnCallGPO@cencora.com.Disclaimer: The OnCall podcast is for educational purposes only and not a substitute for any professional medical advice, legal advice, or clinical judgment. Views expressed are opinions only and not endorsed by Cencora or any of its affiliates. The opinions expressed are solely those of the author and may include certain marketing statements. The content of this presentation is owned or licensed by Cencora, and reproduction of the content is not permitted without Cencora's consent. Neither OnCall nor Cencora control the accuracy of any third-party information. Accessing any referenced site is subject to such site's terms of use.

In this episode, the first of our 505(b)(2) series, sponsored by Avyxa, we are joined by Zach Horstman, Director of Specialty GPO Corporate Accounts for Cencora, and Yoni Resnick, Director of Pharmacy Clinical Services at New England Cancer Specialists, who will discuss the basics of 505(b)(2)s.If you have questions for our guests or suggestions for future topics, send us an email at OnCallGPO@cencora.com.Disclaimer: The OnCall podcast is for educational purposes only and not a substitute for any professional medical advice, legal advice, or clinical judgment. Views expressed are opinions only and not endorsed by Cencora or any of its affiliates. The opinions expressed are solely those of the author and may include certain marketing statements. The content of this presentation is owned or licensed by Cencora, and reproduction of the content is not permitted without Cencora's consent. Neither OnCall nor Cencora control the accuracy of any third-party information. Accessing any referenced site is subject to such site's terms of use.

In this episode, we are joined by Cencora's Specialty Practice Network National Senior Director of Sales for Immunology, Chara Reid, VP Sales for Cencora's Specialty Practice Network, Kortney Cooper, and Elizabeth Johnson, CEO of MedicoCX, who will discuss how buy and bill is implemented in MedicoCX practices.If you have questions for our guests or suggestions for future topics, send us an email at OnCallGPO@cencora.com.Disclaimer: The OnCall podcast is for educational purposes only and not a substitute for professional medical advice or clinical judgement. Views expressed are opinions only and not endorsed by Cencora or affiliates. Neither OnCall nor Cencora control the accuracy of third party information. Accessing those sites is at your own risk and subject of their terms of use.

In this episode, we are joined by Kortney Cooper, VP of Sales for Cencora's Specialty Practice Network, who will discuss the basics of buy and bill.  To find a copy of Kortney's presentation, please visit our OnCall page under Clinical Education on our ION and Specialty Practice Network websites.If you have questions for our guests or suggestions for future topics, send us an email at OnCallGPO@cencora.com.Disclaimer: The OnCall podcast is for educational purposes only and not a substitute for professional medical advice or clinical judgement. Views expressed are opinions only and not endorsed by Cencora or affiliates. Neither OnCall nor Cencora control the accuracy of third party information. Accessing those sites is at your own risk and subject of their terms of use.

In this episode, we are joined by Joel White, President of Horizon Government Affairs, who will discuss the Inflation Reduction Act, PBM reform, drug shortages, Medicare physician payment and telehealth issues.If you have questions for our guests or suggestions for future topics, send us an email at OnCallGPO@cencora.com.Disclaimer: The OnCall podcast is for educational purposes only and not a substitute for professional medical advice or clinical judgement. Views expressed are opinions only and not endorsed by Cencora or affiliates. Neither OnCall nor Cencora control the accuracy of third party information. Accessing those sites is at your own risk and subject of their terms of use.

In this episode, the fourth of our Biosimilars series, Christie Smith discusses the biosimilar payer perspective.If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this episode, the third of our Biosimilars series, Corey Ford, Vice President of Reimbursement and Policy Insights, and Cristina Muñoz, Senior Director of Head of State Government Advocacy discuss legislation surrounding biosimilars.Our next episode will feature information on the biosimilar payer perspective. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this episode, the second of our Biosimilars series, Brian Biehn, Senior Director of Biosimilar Injectables, and Connor Nell, Director of Commercialization Injectables discuss the current Biosimilar landscape and what we can expect to see in the market.Our next episode will feature information on biosimilar legislation. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this episode, the first of our Biosimilars series, Brian Biehn, Senior Director of Biosimilar Injectables, and Connor Nell, Director of Commercialization Injectables discuss Biosimilars 101 and resources to utilize to stay better informed.Our next episode will feature information on the current Biosimilar landscape and what we can expect to see in the market. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com. 

In this episode, the eleventh of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses drug pricing and shortages.If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this episode, the tenth of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses transparency in the House, competition, and lower costs on drugs and services.Our next episode will feature information on drug pricing and shortages. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this episode, the ninth of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses health issues around Medicare physician payment, and PBM reform.Our next episode will feature information on transparency in the House, competition, and lower costs on drugs and services. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this episode, the eighth of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses MPFS, Medicare Drug Price Negotiations, PBM reform, and elections.That's all for this episode of OnCall. Our next episode will feature information on politics and policy, and physician payment issues. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this episode, the seventh of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses Congress and the fiscal backdrop.Our next episode will feature information on issues regarding MPFS, Medicare Drug Price Negotiations, PBM reform, and elections. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this episode, the sixth of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses the new DEA proposed rules on prescribing controlled substances and treatments.Our next episode will feature information on payment updates for Medicare. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this episode, the fifth of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses the End of the Public Health Emergency and what it means for practices.Our next episode will feature information on the New DEA proposed rules on prescribing controlled substances and treatments. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this episode, the fourth of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses federal budget and debt negotiations and the implications for Medicare, Medicaid and ACA.Our next episode will feature information on the end of the Public Health Emergency and what it means for practices. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this episode, the third of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs, and Tony Lee discuss the Inflation Reduction Act, PBM reform, and 2023 regulations.Our next episode will feature information on federal budget and debt negotiations and the implications for Medicare, Medicaid and ACA. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this episode, the second of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs, and Tony Lee discuss drug coverage, pricing, and payment.Our next episode will feature information on the Inflation Reduction Act, PBM reform, and 2023 regulations. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this episode, the first of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs, and Tony Lee discuss three important policy trends impacting physicians: Medicare payments, drugs/biologics, and disparities/SDOH.Our next episode will feature information on drug coverage, pricing, and payments. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this Amgen sponsored podcast, David R. Braxton, MD, Chief of Service for Molecular Pathology at Hoag Hospital, shares his insights as considerations on operationalizing biomarker testing into clinical practice in NSCLC. He discusses considerations on improving the turnaround time of test results, clinical application of ctDNA testing as well as strategies for documentation of results for ease of retrieval. Sponsored by Amgen

In this episode, the fifth of our biosimilar education series, Neil Udovich spoke with Kathy Oubre, CEO of Pontchartrain Cancer Center, about operationalizing biosimilars into practice and the differences and similarities of this process for biosimilars versus their counterparts. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com. 

In this episode, the fourth of our biosimilar education series, Neil Udovich spoke with Kathy Oubre, CEO of Pontchartrain Cancer Center, about the role of the payer in relation to biosimilars, the formulary management process and the differences in treatment of biosimilars by Medicaid and Medicare. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com. 

In this episode, the third of our biosimilar education series, Neil Udovich spoke with Kathy Oubre, CEO of Pontchartrain Cancer Center, about the FDA approval process for biosimilars, the Biologics Price Competition and Innovation Act and safety issues or adverse effects related to biosimilar use. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com. 

In this episode, the second of our biosimilar education series, Kathy Oubre, CEO of Pontchartrain Cancer Center, and Neil Udovich, Vice President of Sales for AmerisourceBergen Specialty GPOs, discuss the history of biosimilars, the reception of them in the medical community and their road ahead. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com. 

In this episode, the first of our biosimilar education series, Kathy Oubre, CEO of Pontchartrain Cancer Center, and Neil Udovich, Vice President of Sales for AmerisourceBergen Specialty GPOs, discuss what biosimilars are (and aren't), interchangeability with their reference products, and Kathy's experience with adopting them into her practice.If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com. 

In this episode, a part of our biomarker testing series, we are joined by Dr. Manish Patel, Director of Drug Development for Florida Cancer Specialists, to talk about biomarker testing in the community oncology setting - from the importance of emerging biomarkers to basket and umbrella trial designs.If you have any questions for today's guest or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.The content and information contained in this podcast is sponsored by Elevation Oncology. This podcast is for educational, and informational purposes only. This podcast does not constitute medical or other professional advice or services. No person should act or refrain from acting on the basis of content provided in any podcast or website without first seeking appropriate medical advice and counseling. The opinions expressed in this podcast are the opinions of the individual and may not reflect the opinions of IntrinsiQ or Elevation Oncology.

In this episode, a part of our biomarker testing series, we are joined by Dr. Manish Patel, Director of Drug Development for Florida Cancer Specialists, to talk about biomarker testing in the community oncology setting - from the advantages and disadvantages of liquid biopsies to the benefits of ordering test panels.If you have any questions for today's guest or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.The content and information contained in this podcast is sponsored by Elevation Oncology. This podcast is for educational, and informational purposes only. This podcast does not constitute medical or other professional advice or services. No person should act or refrain from acting on the basis of content provided in any podcast or website without first seeking appropriate medical advice and counseling. The opinions expressed in this podcast are the opinions of the individual and may not reflect the opinions of IntrinsiQ or Elevation Oncology.

In this podcast series brought to you by Invitae, oncology specialists who routinely integrate genetic information into their patients' treatment, discuss actionable options for implementing genomics-informed, personalized cancer care.In the first installment of this series, Dr. Rakesh Patel, Chief Medical Officer, Digital Health, and Dr. Peter Beitsch, Breast Surgical Oncologist, Past President of the American Society of Breast Surgeons, discuss common barriers for integrating genetic testing, and emerging digital health tools that can help health care practitioners scale the use of genomic information to help their patients.The content and information contained in this podcast is sponsored by Invitae. This podcast is for educational, and informational purposes only. This podcast does not constitute medical or other professional advice or services. No person should act or refrain from acting on the basis of content provided in any podcast or website without first seeking appropriate medical advice and counseling. The opinions expressed in this podcast are the opinions of the individual and may not reflect the opinions of AmerisourceBergen or Invitae.

In the final episode of our buy and bill series, we discuss reducing financial barriers for your patients and talk to Joe Baffone, CEO of Annexus Health, about the benefit of implementing efficient financial navigation programs within your practice.Visit our website for more information or to become a member and ensure you have access to all of our product discounts and rebates, consulting services, upcoming and archived educational content, and all other benefits of a free GPO membership.To learn more about our partners at Annexus Health, visit AnnexusHealth.com.

In this episode, we talk about the reimbursement aspect of the buy and bill model and the four key issues that could negatively impact the health of your revenue cycle.Click here to get in touch with us for more information on this or variety of other topics related to your specialty practice.

In this episode, a part of our biomarker testing series, we are joined by Dr. Manish Patel, Director of Drug Development for Florida Cancer Specialists, to talk about the basics of biomarker testing – from identifying common testing approaches to comparing DNA and RNA sequencing. If you have any questions for today's guest or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com. The content and information contained in this podcast is sponsored by Elevation Oncology. This podcast is for educational, and informational purposes only. This podcast does not constitute medical or other professional advice or services. No person should act or refrain from acting on the basis of content provided in any podcast or website without first seeking appropriate medical advice and counseling. The opinions expressed in this podcast are the opinions of the individual and may not reflect the opinions of IntrinsiQ or Elevation Oncology.

In this episode, we discuss the benefits of buy and bill, how to get reimbursed, steps to take for timely payment and the important role patient assistance plays to protect the practice from financial risk and protect your patients from financial toxicity. Click here to get in touch with us for more information on this or variety of other topics related to your specialty practice.

This is the first episode in our series covering buy and bill. As more drugs that utilize this payment model enter the market, we want to make sure you have the information needed for proper payment and reimbursement.This type of education is just one essential benefit of a free GPO membership. In this episode, we cover the many advantages of a GPO membership and begin our overview of the buy and bill process.Learn more about AmerisourceBergen Specialty GPOs.

The rise of genomic sequencing and use of novel agents in the new standard of cancer care has created new challenges in recognizing and managing toxicities.In this episode, we are joined by Dr. Ian Olver, medical oncologist, bioethicist, researcher and current Professorial Research Fellow in the School of Psychology at the University of Adelaide, to discuss strategies and tools to support community oncologists in keeping patients on effective drugs by better managing the associated toxicities.Learn more about our partners at VieCure.The content and information contained in this podcast is provided [exclusively or solely] by VieCure and AmerisourceBergen is not responsible and does not verify for accuracy any of the information contained in the podcast. The primary purpose of the podcast is to educate and inform. This podcast does not constitute medical or other professional advice or services.

The average oncologist would need 29 hours a day to keep up with the advances in cancer care. There are new treatments, policies, drugs, toxicities, trials—and a shortage of oncologists and nurses. In this episode, we are joined by Dr. Fred Ashbury, co-founder and chief scientific officer at Viecure, to highlight the key areas where A.I. significantly improves your ability to treat patients effectively and efficiently while also adding value to your practice. Learn more about our partners at VieCure.The content and information contained in this podcast is provided [exclusively or solely] by VieCure and AmerisourceBergen is not responsible and does not verify for accuracy any of the information contained in the podcast. The primary purpose of the podcast is to educate and inform. This podcast does not constitute medical or other professional advice or services.

The evolution of cancer care is advancing so quickly, it's nearly impossible to keep up. Genetic sequencing has radically improved our ability to get the right drug to the right patient—improving outcomes for both patients and practices. But policy is unclear, lab testing is interpreted differently, and funding is available—but how do you get it?In this episode, we are joined by Dr. Howard McLeod (internationally recognized expert in precision medicine and medical director for precision medicine at the Geriatric Oncology Consortium) and Dr. Jai Patel (chair of the department of cancer pharmacology and pharmacogenomics at Atrium Health's Levine Cancer Institute) who dive into the paradigm shift in cancer care, the role of genomic testing and sequencing, and navigating policy to your practice's advantage.Learn more about our partners at VieCure.The content and information contained in this podcast is provided [exclusively or solely] by VieCure and AmerisourceBergen is not responsible and does not verify for accuracy any of the information contained in the podcast. The primary purpose of the podcast is to educate and inform. This podcast does not constitute medical or other professional advice or services.

Precision medicine is refocusing which clinical trials are possible, but we still have a ~5% participation rate and non-diverse patient demographic. Community oncology is the doorway to changing the face of clinical trials in the era of precision medicine. In this podcast, we talk about why, how and what's in it for your practice to facilitate clinical trials in the community setting.Learn more about our partners at VieCure.Dr. Paul Bunn Jr., MD, FASCO: Dr. Bunn is a Distinguished Professor​, VieCure Clinical Advisory Council Member, and James Dudley Endowed Chair in Lung Cancer Research​ Division of Medical Oncology University of Colorado.Dr. Fred Ashbury, PhD, MACE: Dr. Ashbury is a co-founder and Chief Scientific Officer at VieCure. He is responsible for developing and maintaining VieCure's oncology clinical content, genomic-science knowledge identification and codification, and the design and implementation of the treatment strategy rules that underpin our platform.The content and information contained in this podcast is provided [exclusively or solely] by VieCure and AmerisourceBergen is not responsible and does not verify for accuracy any of the information contained in the podcast. The primary purpose of the podcast is to educate and inform. This podcast does not constitute medical or other professional advice or services.

Listen to a discussion between Jonathan Abbas, MD, and Mark Levis, MD, PhD.Please listen to additional safety information for TIBSOVO® (ivosidenib tablets) at the end of this presentation. Please visit TibsovoPro.com to review the Full Prescribing Information, including BOXED WARNING.

In this episode, we met with Dr. John Marshall, a medical oncologist, Georgetown University professor and frequent guest speaker at ION Solutions events, and his wife, Liza Marshall, to discuss their book, “Off Our Chests: A Candid Tour Through the World of Cancer”. To learn more or purchase a copy of the book, visit OffOurChestsBook.com.

In this episode Natasha Clinton, Director of Medical Affairs for IntrinsiQ Specialty Solutions, and Nicole Chambers, Senior Director of Corporate Services for ION Solutions, discuss the advancements in liquid and tissue biopsy testing as well as the improvements our partners are making in the precision medicine space.If you have any questions for today's guests or a topic you would like to learn more about, let us know at IONOnCall@gmail.com.

In this episode, a part of our Precision Medicine series, Susan Weidner, Senior VP of IntrinsiQ  Analytics, and Natasha Clinton, Director of Medical Affairs for IntrinsiQ Specialty Solutions, discuss the overall strategy for ION's precision medicine program - from the creation of the Precision Medicine Advisory Panel to where we are headed in the future.If you have any questions for today's guests, or have a topic you would like to hear more about, email IONOnCall@gmail.com.

In this extended episode, Brian Ansay, President of ION and IPN Solutions, sat down with Joe Baffone, Co-Founder and CEO of Annexus Health, to discuss our partnership and the exciting opportunities available to our members. Reach out to your ION or IPN Solutions sales rep or visit the Annexus Health website to learn more.We want to make sure you are getting the most out of our content, so if you have a topic you would like to learn more about, let us know at IONOnCall@gmail.com. 

This is the first episode in what will be our ongoing Precision Medicine series in which we will touch on all aspects of this expanding field, particularly in its relation to community oncology practices. Nicole Chambers, Senior Director of Corporate Services at ION Solutions, and Carol Riley, Practice Manager at St. Louis Cancer Care, will discuss the creation of the Precision Medicine Center, ION's centralized library of Precision Medicine testing recommendations, and its regular use within the processes of one of our practices.If you have any questions for today's guests, or would like to receive a demo of the Precision Medicine Center, email IONOnCall@gmail.com. We also want to make sure you are getting the most out of our content, so if you have a topic you would like to learn more about, let us know.